My research interests primarily focus on breast cancer, lung cancer and early drug development.
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol (2019). PMID: 31465093
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol (2019) 5(1):74-82. PMID: 30242306
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med (2018) 379(22):2108-2121. PMID: 30345906
Cancer Immune Therapy
I lead the cancer immunotherapy group at Barts with Professor Thomas Powles, overseeing clinical and translational research on immune checkpoint inhibitors and other immune strategies. The group currently runs more than 10 early clinical trials of single agent or combination cancer immunotherapy treatments, focusing on breast, genitourinary and thoracic cancers.
We are now researching epigenetic 'signatures' of different cancers in order to treat patients with the right medicine for their specific disease. We focus on the role of epigenetics in therapeutic resistance. The aim is to match medicines to patients and reduce the number of patients needlessly subjected to uncomfortable side effects. During this genetic and epigenetic mapping, we also aim to find new cancer-specific targets for drug development.
Novel DNA Damage and Stability Biomarkers and Therapeutic Targets
Over the next 5 years, a variety of novel DDR and chromatin maintenance mechanisms will be validated and, in collaboration with the newly appointed Chairs in Drug Discovery and Medicinal Chemistry, potential inhibitors for synthetic lethality strategies will be identified.
Trials Targeting Therapeutic Resistance
Two international window-of-opportunity trials that Professor Schmid leads focus on establishing the role of targeting the androgen receptor (AR) in early breast cancer, using the novel anti-androgen Enzalutamide:
I also lead a national clinical trial that investigates whether the addition of the HSP27-targeting antisensce oligoneucleotide Apatorsen to chemotherapy can improve the outcome of patients with squamous cell lung cancers.
These trials are supported by NIHR and CRUK funding to the Barts/Brighton Experimental Cancer Medicine Centre. UK recruitment is also supported by the NIHR Cancer Research Network and the UK Experimental Cancer Medicine Centre network.
Our international collaborative group studies circulating biomarkers for screening, diagnosis, patient management and surveillance of breast cancers. The programme includes:
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage Verrill M, Wardley AM, Retzler J et al. Health and Quality of Life Outcomes (2020) 18(7)
The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer Harder H, Shilling VM, May SF et al. Breast Cancer Research and Treatment (2020) 183(7) 629-638
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer Robertson JFR, Evans A, Henschen S et al. Clinical cancer research : an official journal of the American Association for Cancer Research (2020) 26(7) 4242-4249
Evaluation of pathologic complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer Huang M, O'Shaughnessy J, Zhao J et al. JNCCN Journal of the National Comprehensive Cancer Network (2020) 18(7) 1096-1104
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply Schmid P, Dent R, O'Shaughnessy J The New England journal of medicine (2020) 382(7) e108
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer Adams S, Diéras V, Barrios CH et al. Annals of Oncology (2020) 31(7) 582-589
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study Schmid P, Salgado R, Park YH et al. Annals of Oncology (2020) 31(7) 569-581
Pembrolizumab plus Neoadjuvant Chemotherapy Improves Pathologic Complete Response Rates in Triple-Negative Breast Cancer Schmid P, Cortes L, Pusztai L Journal of Clinical Outcomes Management (2020) 27(7) 53-55
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer Rugo HS, Bardia A, Tolaney SM et al. Future Oncology (2020) 16(7) 705-712
Enhancing global access to cancer medicines Cortes J, Perez-García JM, Llombart-Cussac A et al. CA Cancer Journal for Clinicians (2020) 70(7) 105-124For additional publications, please click here